Immunoprecise Antibodies Ltd
XTSX:IPA
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
CA |
Immunoprecise Antibodies Ltd
XTSX:IPA
|
161.4m CAD | -15.2 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
229.3B USD | 23.5 | ||
US |
Danaher Corp
NYSE:DHR
|
187.7B USD | 16.9 | ||
US |
Agilent Technologies Inc
NYSE:A
|
43.9B USD | 28.3 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
42.5B USD | 16.9 | ||
CH |
Lonza Group AG
SIX:LONN
|
37.9B CHF | 19.9 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
56T KRW | 34.4 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
32.3B USD | 28.3 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.6B USD | 32.5 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
26.1B USD | 17.2 | ||
US |
Waters Corp
NYSE:WAT
|
20.8B USD | 23.2 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.